HDAC6: Tumor Progression and Beyond.

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Histone Deacetylase 6 (HDAC6) is unique among HDACs, primarily located in the cytoplasm.
• It possesses two catalytic domains and a distinct ubiquitin-binding domain.
• HDAC6 deacetylates non-histone substrates like α-tubulin, HSP90, and cortactin.

Purpose of the Study:

• To review the structural characteristics of HDAC6.
• To elucidate the biological functions of HDAC6 in tumor progression.
• To discuss the therapeutic potential of HDAC6 inhibitors in cancer treatment.

Main Methods:

• Review of existing literature on HDAC6 structure and function.
• Analysis of HDAC6's role in key cancer hallmarks.
• Compilation of data from preclinical and clinical trials of HDAC6 inhibitors.

Main Results:

• HDAC6 influences tumor invasion, metastasis, angiogenesis, drug resistance, stemness, and immune evasion.
• Selective HDAC6 inhibitors are being investigated for solid and hematological tumors.
• Several HDAC6 inhibitors have entered clinical trials with positive preliminary results.

Conclusions:

• HDAC6 is a significant therapeutic target in oncology.
• Targeting HDAC6 offers a promising strategy for cancer therapy.
• Ongoing clinical trials are evaluating the efficacy of HDAC6 inhibitors.